Abzena reveals plans for new biologics cGMP site

Due to an increase in customer demand for commercial scale 2000L single use bioreactors across various therapeutic sectors, Abzena will add a sixth global site that will expand current good manufacturing practice (cGMP) manufacturing capacity for mammalian biologics, the life sciences group says.

Construction of the site is expected to begin mid-2022.

The new facility will be in the US and will be home to Phase III and commercial manufacturing. A phased approach to construction will initially allow four modular suites, with each suite including up to two 2000L bioreactors, followed by the addition of two further 2000L suites.